

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 January 2010 (14.01.2010)

PCT

(10) International Publication Number
WO 2010/003996 A1

(51) International Patent Classification:

A61K 9/46 (2006.01) *A61P 9/04* (2006.01)
A61K 31/4178 (2006.01) *A61P 9/12* (2006.01)
A61K 31/549 (2006.01) *A61P 13/12* (2006.01)

Solvay Pharmaceuticals B.V., C.J. van Houtenlaan 36,
NL-1381 CP Weesp (NL).

(21) International Application Number:

PCT/EP2009/058724

(74) Agent: **VERHAGE, Marinus**; Octrooibureau Zoan B.V.,
P.O. Box 140, NL-1380 AC Weesp (NL).

(22) International Filing Date:

9 July 2009 (09.07.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/080,067 11 July 2008 (11.07.2008) US
08160211.2 11 July 2008 (11.07.2008) EP

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US):
SOLVAY PHARMACEUTICALS B.V. [NL/NL]; C.J.
van Houtenlaan 36, NL-1381 CP Weesp (NL).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LINK, Paulus A. J.**
[NL/NL]; Solvay Pharmaceuticals B.V., C.J. van Houten-
laan 36, NL-1381 CP Weesp (NL). **VAN DER HULST,**
Marcellus M. [NL/NL]; Solvay Pharmaceuticals B.V.,
C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). **BIE-**
LENBERG, Gerhard-Wilhelm [DE/DE]; Solvay Phar-
maceuticals B.V., C.J. van Houtenlaan 36, 1381 CP
Weesp (DE). **VAN DEN AKKER, Cornelis R.** [NL/NL];

Published:

— with international search report (Art. 21(3))

(54) Title: EPROSARTAN COMPOSITIONS

(57) Abstract: The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (All) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg.



WO 2010/003996 A1